Shandong Xinhua Pharmaceutical Company Limited Class H (HK:0719) has released an update.
Shandong Xinhua Pharmaceutical Company Limited has announced the successful acquisition of the Drug Registration Certificate for its pregabalin capsules, which are used to treat post-herpetic neuralgia and fibromyalgia, from the National Medical Products Administration. This milestone, which confirms the product’s compliance with drug registration requirements, positions the company for the production and sale of the medication in compliance with pharmaceutical quality standards.
For further insights into HK:0719 stock, check out TipRanks’ Stock Analysis page.
